Bortezomib in Patients With Chronic Graft Versus Host Disease

Status Completed

Clinical Trial Summary

This study will investigate whether bortezomib can control the immune system and can be used to treat GVHD. Bortezomib has been used with not too many serious side effects in patients with multiple myeloma who will undergo transplant and also for acute graft versus host disease.

Clinical Trial Description

Bone marrow transplantation offers great promise for the treatment of a variety of diseases, particularly hematological malignancies. The incidence of acute GVHD has significantly decreased due to significant improvements in human leukocyte antigen (HLA) matching of the donors and recipients, more efficient GVHD prophylaxis regimens and the use of reduced-intensity preparative regimen. However, cGVHD remains a significant cause for increased morbidity and mortality associated with allogeneic stem cell transplantation.

While many of the patients with cGVHD respond initially to higher doses of steroids, cGVHD usually relapses during or following steroid taper. Because of the significant impact of steroids on this patient population, there is an urgent need for medications to take the place of high dose steroid use in this patient population.

We hypothesize that bortezomib can modulate the immune system and can be used to treat GVHD. At the same time bortezomib post transplant can induce a graft versus leukemia or lymphoma effect. Bortezomib has been used with minimal toxicity in post transplant setting for patients with aggressive multiple myeloma and also for acute graft versus host disease. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01672229
Study type	Interventional
Source	University of California, Davis
Contact
Status	Completed
Phase	Phase 1
Start date	July 2012
Completion date	April 9, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03357159` - Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation	Phase 2
Completed	`NCT00003270` - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer	Phase 2
Terminated	`NCT02877082` - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients	Phase 2
Recruiting	`NCT01385124` - Cannabidiol for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation	Phase 1/Phase 2
Withdrawn	`NCT01616680` - Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease	Phase 2
Recruiting	`NCT01810926` - T&B Depletion Non Malignant	Phase 2
Completed	`NCT01379209` - Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)	Phase 1/Phase 2
Completed	`NCT01233921` - Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer	N/A
Recruiting	`NCT00986557` - T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant	Phase 2
Enrolling by invitation	`NCT00972660` - Safety and Efficacy Study of Allogenic Mesenchymal Stem Cells to Treat Extensive Chronic Graft Versus Host Disease	Phase 2
Terminated	`NCT00555048` - Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer	Phase 1/Phase 2
Terminated	`NCT00373815` - Everolimus in Combination With Cyclosporine A and Prednisolone for the Treatment of Graft Versus Host Disease	Phase 1
Terminated	`NCT00608517` - Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil	N/A
Completed	`NCT00056875` - Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants	Phase 1/Phase 2
Recruiting	`NCT05808985` - Intestinal Microbiome-based Research for the Prevention of Acute GVHD	Phase 2
Completed	`NCT00813618` - Study of MEDI 507 in the Treatment of Pediatric Patients	Phase 1
Completed	`NCT00003398` - Bone Marrow Transplantation in Treating Patients With Hematologic Cancer	Phase 4
Terminated	`NCT00005641` - Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation	Phase 2
Completed	`NCT02663622` - Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)	Phase 2
Completed	`NCT00577278` - A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan	Phase 2